The ghrelin receptor antisense long non-coding RNA gene, GHSROS, as a potential target for prostate cancer therapy
The specific aims that will be addressed in this study are:
-
To characterise the subgroup of clinical prostate cancers which express high levels of GHSROS using RNA in situ hybridisation and quantitative RT-PCR in order to correlate expression with clinical data and outcomes;
-
To investigate the role of GHSROS in tumour growth, invasion and metastasis using orthotopic (intraprostatic) xenograft models; and
-
To investigate the effect of GHSROS silencing on prostate tumour growth in vivo using a xenograft model and locked nucleic acid antisense oligonucleotides.
Investigators
Duration
2016 - 2017
Funding
| Cancer Council Queensland | $200 000 |
